About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients.
A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons.
advertisement
NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Digital health funding stays low as a new reality sets in
Next article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： As demand for Covid shots wanes, Moderna seeks its next success
